BCDA Setting up for a Long? I'm adding a new stock to my watchlist. $BCDA has Market Cap of 36.28 M and an Enterprise Value of 31.32 M. It has 31.3% insider ownership with the management buying shares each month since September 2022 through December 2022. They create cellular therapeutics for cardiovascular diseases. Their rev
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.34 USD
−7.95 M USD
58.00 K USD
3.69 M
About BioCardia, Inc.
Sector
Industry
CEO
Peter Alan Altman
Website
Headquarters
Sunnyvale
Founded
1994
FIGI
BBG000BTJTF3
BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
BCDA Short AnalysisBCDA has an upcoming CardiAMP Heart Failure DSMB review on the 30th of this month (August). Although the treatment indicated no significant safety concerns, I have reasonable doubt that this won't go through to be accepted by the FDA; the Phase III to NDA/BLA is about a 58.1% chance, the NDA/BLA to
$BCDA is gonna fall todayPupm&Dump trading strategy idea.
$BCDA is rising without clear preconditions today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $5,04;
stop-loss — $5,49;
take-profit — $4,
BioCardia Anticipates DSMB Feedback on Interim Data1. BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial
BCDA today announces that it anticipates data safety monitoring board (DSMB) verbal feedback by the end of December 15, 2020 on interim data from the Company’s pivotal Phase 3 CardiAMP Heart Fa
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of BCDA is 1.80 USD — it has increased by 0.52% in the past 24 hours. Watch BioCardia, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BioCardia, Inc. stocks are traded under the ticker BCDA.
BCDA stock has fallen by −0.52% compared to the previous week, the month change is a −25.87% fall, over the last year BioCardia, Inc. has showed a −67.57% decrease.
We've gathered analysts' opinions on BioCardia, Inc. future price: according to them, BCDA price has a max estimate of 6.00 USD and a min estimate of 6.00 USD. Watch BCDA chart and read a more detailed BioCardia, Inc. stock forecast: see what analysts think of BioCardia, Inc. and suggest that you do with its stocks.
BCDA reached its all-time high on Feb 23, 2000 with the price of 78,501.71 USD, and its all-time low was 1.63 USD and was reached on Dec 19, 2024. View more price dynamics on BCDA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BCDA stock is 7.78% volatile and has beta coefficient of 2.19. Track BioCardia, Inc. stock price on the chart and check out the list of the most volatile stocks — is BioCardia, Inc. there?
Today BioCardia, Inc. has the market capitalization of 8.99 M, it has increased by 2.50% over the last week.
Yes, you can track BioCardia, Inc. financials in yearly and quarterly reports right on TradingView.
BioCardia, Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
BCDA net income for the last quarter is −2.30 M USD, while the quarter before that showed −1.74 M USD of net income which accounts for −32.18% change. Track more BioCardia, Inc. financial stats to get the full picture.
No, BCDA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 21, 2025, the company has 20 employees. See our rating of the largest employees — is BioCardia, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioCardia, Inc. EBITDA is −7.57 M USD, and current EBITDA margin is −13.05 K%. See more stats in BioCardia, Inc. financial statements.
Like other stocks, BCDA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioCardia, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioCardia, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioCardia, Inc. stock shows the sell signal. See more of BioCardia, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.